Fig. 4

Validation of predictive role of CD8 and PD-L1 expression in a cohort of patients treated with nivolumab or pembrolizumab. a, b Kaplan–Meier estimates for progression-free survival; patients were stratified according to CD8A (a) and CD274 (b) mRNA expression: low expression (in red) and high expression (in blue). c Kaplan–Meier estimates for progression-free survival; patients were stratified in two groups: a group with high CD8A and CD274 mRNA expression (CD8A+ CD274+) and a group with the other patients. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significant